View source for 7ifi


==Crystal structure of Endothiapepsin in complex with fragment EOS102469 from ECBL-96==
<StructureSection load='7ifi' size='340' side='right'caption='[[7ifi]], [[Resolution|resolution]] 1.15&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[7ifi]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Cryphonectria_parasitica Cryphonectria parasitica]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7IFI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7IFI FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.15&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1CGP:[(3~{R},4~{S})-4-thiophen-3-ylpyrrolidin-3-yl]methanol'>A1CGP</scene>, <scene name='pdbligand=A1CGQ:[(3S,4R)-4-(thiophen-3-yl)pyrrolidin-3-yl]methanol'>A1CGQ</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7ifi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7ifi OCA], [https://pdbe.org/7ifi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7ifi RCSB], [https://www.ebi.ac.uk/pdbsum/7ifi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7ifi ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/CARP_CRYPA CARP_CRYPA] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Quite frequently, it is the progression of initial crystallographic fragment screening hits into more potent binders to their target, which constitutes the major bottleneck in many academic compound or drug development projects. While high quality starting points are critical to the success of a drug development project, it is equally important to have accessible pathways for further compound development. Here, we present two crystallographic fragment screening campaigns using a 96 fragment sub-selection of the European Fragment Screening Library (EFSL) provided by EU-OPENSCREEN. The two campaigns against the targets endothiapepsin and the NS2B-NS3 Zika protease, yielded hit rates of 31% and 18%, respectively. Further, we present how within the framework of the EU-OPENSCREEN European Research Infrastructure Consortium (ERIC) fast identification of follow-up compounds can be realized. With just one round of testing related compounds from the European Chemical Biology Library, two follow-up binders for each of the two targets could be identified proving the feasibility of this approach.

From fragments to follow-ups: rapid hit expansion by making use of EU-OPENSCREEN resources.,Benz LS, Wollenhaupt J, Jirgensons A, Miletic T, Mueller U, Weiss MS RSC Med Chem. 2025 Oct 22. doi: 10.1039/d5md00684h. PMID:41132859<ref>PMID:41132859</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 7ifi" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Cryphonectria parasitica]]
[[Category: Large Structures]]
[[Category: Benz LS]]
[[Category: Jirgensons A]]
[[Category: Miletic T]]
[[Category: Mueller U]]
[[Category: Weiss MS]]
[[Category: Wollenhaupt J]]